These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24370686)

  • 21. Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol.
    Lee JC; Ahn S; Paik KH; Kim HW; Kang J; Kim J; Hwang JH
    BMJ Open; 2016 Mar; 6(3):e010491. PubMed ID: 27016245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials.
    Liu B; Bo Y; Wang K; Liu Y; Tang X; Zhao Y; Zhao E; Yuan L
    Oncotarget; 2017 Mar; 8(12):20410-20417. PubMed ID: 28099899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications.
    Verma V; Li J; Lin C
    Am J Clin Oncol; 2016 Jun; 39(3):302-13. PubMed ID: 26950464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades.
    Nishikawa G; Banik P; Thawani R; Kardosh A; Wood SG; Nabavizadeh N; Chen EY
    J Gastrointest Oncol; 2022 Jun; 13(3):1454-1466. PubMed ID: 35837173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant treatments for resectable rectal cancer: A network meta-analysis.
    Zhong W; Xue X; Dai L; Li R; Nie K; Zhou S
    Exp Ther Med; 2020 Apr; 19(4):2604-2614. PubMed ID: 32256740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy.
    Joo I; Lee JM; Lee ES; Ahn SJ; Lee DH; Kim SW; Ryu JK; Oh DY; Kim K; Lee KB; Jang JY
    AJR Am J Roentgenol; 2018 May; 210(5):1059-1065. PubMed ID: 29489408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.
    Rangarajan K; Pucher PH; Armstrong T; Bateman A; Hamady Z
    Ann R Coll Surg Engl; 2019 Sep; 101(7):453-462. PubMed ID: 31304767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
    Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
    Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is neoadjuvant chemoradiotherapy for pancreatic cancer beneficial: A systematic review and meta-analysis.
    Luo W; Wang Y; Tao Y; Zhang T
    Front Oncol; 2022; 12():979390. PubMed ID: 36505795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis.
    Lee YS; Lee JC; Yang SY; Kim J; Hwang JH
    Sci Rep; 2019 Oct; 9(1):15662. PubMed ID: 31666626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis.
    Yan M; Kumachev A; Siu LL; Chan KK
    Eur J Cancer; 2015 Aug; 51(12):1570-9. PubMed ID: 26044925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
    Amin S; Baine M; Meza J; Lin C
    BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis.
    Ma HF; Lv GX; Cai ZF; Zhang DH
    Onco Targets Ther; 2018; 11():3441-3447. PubMed ID: 29942136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
    Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
    PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
    An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
    Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials.
    Hajibandeh S; Hajibandeh S; Intrator C; Hassan K; Sehmbhi M; Shah J; Mazumdar E; Kausar A; Satyadas T
    Ann Hepatobiliary Pancreat Surg; 2023 Feb; 27(1):28-39. PubMed ID: 36536501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study).
    Zhou HY; Zheng SP; Li AL; Gao QL; Ou QY; Chen YJ; Wu ST; Lin DG; Liu SB; Huang LY; Li FS; Zhu HY; Qiao GB; Lanuti M; Yao HR; Yu YF
    EClinicalMedicine; 2020 Jul; 24():100422. PubMed ID: 32637899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis.
    Malthaner RA; Wong RK; Rumble RB; Zuraw L;
    BMC Med; 2004 Sep; 2():35. PubMed ID: 15447788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
    Gebski V; Burmeister B; Smithers BM; Foo K; Zalcberg J; Simes J;
    Lancet Oncol; 2007 Mar; 8(3):226-34. PubMed ID: 17329193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.